Clinuvel PharmaceuticalsASX:CUV -0.68%81 Dividend Payout Ratio is 0.24 as of Dec. 2025, which is 243% above its 10-year median of 0.07. GuruFocus rates ASX:CUV with a GF Score™ of 81/100 and a GF Value™ of A$17.71 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 134 Biotechnology companies, Clinuvel Pharmaceuticals ranks better than 93.28% on this metric.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Clinuvel Pharmaceuticals's Dividend Payout Ratio for the
months ended in Dec. 2025 was 0.24.
The historical rank and industry rank for Clinuvel Pharmaceuticals's Dividend Payout Ratio or its related term are showing as below:
ASX:CUV'
s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.05 Med: 0.07 Max: 0.08
Current: 0.08
During the past 13 years, the highest Dividend Payout Ratio of Clinuvel Pharmaceuticals was 0.08. The lowest was 0.05. And the median was 0.07.
ASX:CUV's Dividend Payout Ratio is ranked better than 93.28% of 134
companies
in the Biotechnology industry
Industry Median: 0.445
vs ASX:CUV: 0.08
During the past 13 years, the highest Trailing Annual Dividend Yield of Clinuvel Pharmaceuticals was 0.56%. The lowest was 0.05%. And the median was 0.14%.
During the past 3 years, the average Dividends Per Share Growth Rate was 26.00% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 18.80% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Clinuvel Pharmaceuticals was 26.00% per year. The lowest was 7.70% per year. And the median was 21.50% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Clinuvel Pharmaceuticals (ASX:CUV) Dividend Payout Ratio Explanation
In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Clinuvel Pharmaceuticals Dividend Payout Ratio Related Terms
Clinuvel Pharmaceuticals Dividend Payout Ratio Historical Data
* Premium members only.
The historical data trend for Clinuvel Pharmaceuticals's Dividend Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinuvel Pharmaceuticals Dividend Payout Ratio Chart
ASX:CUV vs VRTX, REGN, ALNY: Dividend Payout Ratio Comparison
For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinuvel Pharmaceuticals Dividend Payout Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Dividend Payout Ratio distribution charts can be found below:
* The bar in red indicates where Clinuvel Pharmaceuticals's Dividend Payout Ratio falls into.
Clinuvel Pharmaceuticals Dividend Payout Ratio Calculation
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.
Clinuvel Pharmaceuticals's Dividend Payout Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinuvel Pharmaceuticals (ASX:CUV) has a Dividend Payout Ratio of 0.24 as of Dec. 2025. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Clinuvel Pharmaceuticals and its competitors. This is 243% above median its historical median of 0.07. Over the past decade, Clinuvel Pharmaceuticals' Dividend Payout Ratio has ranged from 0.05 to 0.08. According to the industry distribution chart, Clinuvel Pharmaceuticals ranks #9 out of 134 companies in the Biotechnology industry, placing it in the top 6.7%.
Is Clinuvel Pharmaceuticals' Dividend Payout Ratio too high?
Clinuvel Pharmaceuticals' current Dividend Payout Ratio of 0.24 is 243% above median its 10-year median of 0.07. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 0.08. The Biotechnology industry median Dividend Payout Ratio is 0.45. Clinuvel Pharmaceuticals' value of 0.24 is 46.1% below this industry median. Based on the distribution chart, Clinuvel Pharmaceuticals ranks #9 out of 134 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Clinuvel Pharmaceuticals has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Clinuvel Pharmaceuticals' Dividend Payout Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clinuvel Pharmaceuticals ranks #9 out of 134 companies for Dividend Payout Ratio. This places Clinuvel Pharmaceuticals in the top 7% of its industry — outperforming the majority of peers. The industry median Dividend Payout Ratio is 0.45. Clinuvel Pharmaceuticals' value of 0.24 is 46.1% below this benchmark. Historically, Clinuvel Pharmaceuticals' own Dividend Payout Ratio has ranged from 0.05 to 0.08 over the past decade. While the company's 10-year median is 0.07 vs. the industry median of 0.45, Clinuvel Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Biotechnology company?
The median Dividend Payout Ratio among Biotechnology companies is 0.45, based on 134 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clinuvel Pharmaceuticals's current Dividend Payout Ratio of 0.24 is 46.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Clinuvel Pharmaceuticals and its competitors. For the Biotechnology industry, the median Dividend Payout Ratio is 0.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinuvel Pharmaceuticals's current Dividend Payout Ratio is 0.24, which is 243% above median its own 10-year median of 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinuvel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals (ASX:CUV) is currently considered Significantly Undervalued. The stock's GF Value™ is A$17.71, compared to a current price of A$10.28 — trading 42% below its estimated fair value. The current Dividend Payout Ratio is 0.24, which is 243% above median its 10-year median of 0.07 and 46.1% below the Biotechnology industry median of 0.45. Clinuvel Pharmaceuticals' overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (ASX:CUV), the current Dividend Payout Ratio is 0.24 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinuvel Pharmaceuticals (ASX:CUV) Overvalued in 2026?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued.
The current stock price of A$10.28 is trading 42% below its estimated GF Value™ of A$17.71.
GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for ASX:CUV:
Dividend Payout Ratio: 0.24 (243% above median its 10-year median of 0.07)
GF Value™: A$17.71 vs. price of A$10.28 (42% below fair value)
Industry Position: 46.1% below the Biotechnology median (#9 of 134)
No single metric tells the full story. See the ASX:CUV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
81GF Score
Get the complete analysis for ASX:CUV
Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CUV has been successfully added to your 
